ABSTRACT
AIM: To assess activity and safety of erythropoietin (EP) drugs in conservative chronic renal failure (CRF). MATERIAL AND METHODS: The antianemic effect of EP drugs, central and cardiac hemodynamics were studied in 28 CRF patients (mean blood creatinine 5.27 mg%) with renal anemia. In addition, arterial pressure was automatically measured within 24 hours and the CRF progression rate was assessed. RESULTS: Low-dose EP drugs injected subcutaneously rapidly produced antianemic and cardioprotective effects and may improve residual renal function. CONCLUSION: Pathogenetically grounded and safe for patients with conservative CRF is a combination of low-dose subcutaneous EP drugs with hypotensive drugs (calcium antagonists, ACE inhibitors), loop diuretics and low-protein diet.
